NasdaqGS:SYREBiotechs
Spyre Therapeutics (SYRE): Evaluating Valuation Following Encouraging SPY003 Trial Results and Improved Financials
Spyre Therapeutics (SYRE) drew attention after releasing encouraging interim results from its Phase 1 trial of SPY003, in addition to reporting a substantial year-over-year improvement in both quarterly and nine-month net losses.
See our latest analysis for Spyre Therapeutics.
On the heels of upbeat clinical trial news and a slimmer quarterly net loss, Spyre Therapeutics has seen momentum pick up, with a recent 90-day share price return of 38.7%. However, despite these gains, the one-year...